1921
Volume 99, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

HIV-positive adults on treatment for multi drug-resistant tuberculosis (MDR-TB) experience high mortality. Biomarkers of HIV/MDR-TB treatment response may enable earlier treatment modifications that improve outcomes. To determine whether changes in C-reactive protein (CRP), D-dimer, and fibrinogen were associated with treatment outcome among those with HIV/MDR-TB coinfection, we studied 20 HIV-positive participants for the first 16 weeks of MDR-TB therapy. Serum CRP, fibrinogen, and D-dimer were measured at baseline and serially while on treatment. At baseline, all biomarkers were elevated above normal levels, with median CRP 86.15 mg/L (interquartile range [IQR] 29.25–149.32), D-dimer 0.85 µg/mL (IQR 0.34–1.80), and fibrinogen 4.11 g/L (IQR 3.75–6.31). C-reactive protein decreased significantly within 10 days of treatment initiation and fibrinogen within 28 days; D-dimer did not change significantly. Five (25%) participants died after a median of 32 days. Older age (median age of 38 among survivors and 54 among deceased, = 0.008) and higher baseline fibrinogen (3.86 g/L among survivors and 6.37 g/L among deceased, = 0.02) were significantly associated with death. After adjusting for other measured variables, higher CRP concentrations at the beginning of each measurement interval were significantly associated with a higher risk of death during that interval. Trends in fibrinogen and CRP may be useful for evaluating early response to treatment among individuals with HIV/MDR-TB coinfection.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0322
2018-09-17
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/5/tpmd180322.html?itemId=/content/journals/10.4269/ajtmh.18-0322&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2017. Global Tuberculosis Report 2017. Geneva, Switzerland: WHO. [Google Scholar]
  2. Boehme CC, 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 14951505. [Google Scholar]
  3. Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K, , 2014. The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2014: CD010705. [Google Scholar]
  4. STOP TB Department, Department of HIV/AIDS, 2007. Improving the Diagnosis and Treatment of Smear-Negative Pulmonary and Extrapulmonary Tuberculosis among Adults and Adolescents: Recommendations for HIV-Prevalent and Resource-Constrained Settings. Available at: http://apps.who.int/iris/handle/10665/69463. Accessed January 3, 2018.
  5. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS, , 2012. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 16: 9097. [Google Scholar]
  6. World Health Organization, 2014. Companion Handbook to the 2011 WHO Guidelines for the Programmatic Management of Multidrug-Resistant Tuberculosis. Geneva, Switzerland: WHO. [Google Scholar]
  7. World Health Organization, Stop TB Initiative, 2010. Treatment of Tuberculosis: Guidelines, 4th edition. Geneva, Switzerland: WHO. [Google Scholar]
  8. Kwan CK, Ernst JD, , 2011. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 24: 351376. [Google Scholar]
  9. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai W, Rodriguez W, Bassett IV, , 2014. Evaluating diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis 14: 239249. [Google Scholar]
  10. Yoon C, Chaisson LH, Patel SM, Allen IE, Drain PK, Wilson D, Cattamanchi A, , 2017. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 21: 10131019. [Google Scholar]
  11. Miranda P, Gil-Santana L, Oliveira MG, Mesquita EDD, Silva E, Rauwerdink A, Cobelens F, Oliveira MM, Andrade BB, Kritski A, , 2017. Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation. PLoS One 12: e0175278. [Google Scholar]
  12. Singanayagam A, Manalan K, Connell DW, Chalmers JD, Sridhar S, Ritchie AI, Lalvani A, Wickremasinghe M, Kon OM, , 2016. Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis. Int J Tuberc Lung Dis 20: 16531660. [Google Scholar]
  13. Mendy J, Togun T, Owolabi O, Donkor S, Ota MOC, Sutherland JS, , 2016. C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in the Gambia. BMC Infect Dis 16: 115. [Google Scholar]
  14. Mesquita EDD, Gil-Santana L, Ramalho D, Tonomura E, Silva EC, Oliveira MM, Andrade BB, Kritski A, Rede-TB Study Group; , 2016. Associations between systemic inflammation, mycobacterial loads in sputum and radiological improvement after treatment initiation in pulmonary TB patients from Brazil: a prospective cohort study. BMC Infect Dis 16: 368. [Google Scholar]
  15. Kager LM, 2015. Pulmonary tuberculosis induces a systemic hypercoagulable state. J Infect 70: 324334. [Google Scholar]
  16. Janssen S, 2017. Hemostatic changes associated with increased mortality rates in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. J Infect Dis 215: 247258. [Google Scholar]
  17. Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E, Ozturk A, Ilvan A, , 2002. Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis 6: 927932. [Google Scholar]
  18. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA, , 2013. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 8: e61002. [Google Scholar]
  19. Wyndham-thomas C, Corbiere V, Selis E, Payen M, Goffard J, Vooren JV, Mascart F, Dirix V, , 2017. Immune activation by Mycobacterium tuberculosis in HIV-infected and -uninfected subjects. J Acquir Immune Defic Syndr 74: 103111. [Google Scholar]
  20. Becattini C, Lignani A, Masotti L, Forte MB, Agnelli G, , 2012. D-dimer for risk stratification in patients with acute pulmonary embolism. J Thromb Thrombolysis 33: 4857. [Google Scholar]
  21. Massyn N, Peer N, English R, Padarath A, Barron P, Day C, , 2016. District Health Barometer 2015/16. Durban, South Africa: Health Systems Trust. Available at: http://www.hst.org.za/publications/district-health-barometer-201516-0. Accessed May 2, 2017.
  22. Department of Health, Republic of South Africa, 2015. Introduction of New Drugs and Drug Regimens for the Management of Drug-Resistant Tuberculosis in South Africa: Policy Framework v1.1. Available at: http://www.nicd.ac.za/assets/files/Acrobat%20Document.pdf. Accessed November 22, 2017.
  23. Department of Health, Republic of South Africa, 2014. National Tuberculosis Management Guidelines 2014. Pretoria, South Africa: Department of Health. [Google Scholar]
  24. Benjamini Y, Hochberg Y, , 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289300. [Google Scholar]
  25. Warren JL, Gordon-Larsen P, , 2018. Factors associated with supermarket and convenience store closure: a discrete time spatial survival modelling approach. J R Stat Soc Ser A Stat Soc 181: 783802. [Google Scholar]
  26. Allison PD, , 2010. Survival Analysis Using SAS: A Practical Guide. 2nd edition. Cary, NC: SAS Press. [Google Scholar]
  27. R Core Team, 2017. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org/. Accessed August 1, 2017.
  28. Youden WJ, , 1950. Index for rating diagnostic tests. Cancer 3: 3235. [Google Scholar]
  29. Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH, , 2012. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 7: e31786. [Google Scholar]
  30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, , 2009. Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377381. [Google Scholar]
  31. Wickham H, , 2016. Ggplot2: Elegant Graphics for Data Analysis. 2nd edition. New York, NY: Springer-Verlag. [Google Scholar]
  32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M, , 2011. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77. [Google Scholar]
  33. Schnippel K, Shearer K, Evans D, Berhanu R, Dlamini S, Ndjeka N, , 2015. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int J Infect Dis 39: 8994. [Google Scholar]
  34. Nardell EA, , 2016. Transmission and institutional infection control of tuberculosis. Cold Spring Harb Perspect Med 6: a018192. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0322
Loading
/content/journals/10.4269/ajtmh.18-0322
Loading

Data & Media loading...

Supplemental files

  • Received : 16 Apr 2018
  • Accepted : 13 Jul 2018
  • Published online : 17 Sep 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error